Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

Abstract: Disclosed herein are methods for promoting healthy neural development in an unborn baby, which include administering to a maternal subject gestating the unborn baby a composition or a bacterial composition. Compositions can include trimethylamine N-oxide (TMAO), 5-aminovalerate (5-AV), imidazole propionate (IP), hippurate (HIP), or a combination thereof, and the bacterial compositions can include bacteria of the order Clostridiales. Also disclosed are methods for conditioning a female subject for bringing about offspring with healthy neural development. Additionally disclosed are methods for reducing adverse effects of antibiotic treatment on an unborn baby in a pregnant subject. Also disclosed are methods for selecting a female subject for conditioning to foster healthy neural development in offspring.

Abstract: The present disclosure provides methods of treating hypoxia-induced cognitive impairment. Also disclosed are microbiome modulators, such as ketogenic-diet-suppressed bacterial species or antibiotics effective against a ketogenic-diet-boosted bacterial species, for use in treatment of cognitive impairment. The disclosure also provides methods of selecting a subject having hypoxia-induced cognitive impairment and methods of obtaining a prognostic indicator of hypoxia-induced cognitive impairment in a subject who receives a dosage of a microbiome modulator.

Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

Abstract: Disclosed herein are methods for promoting fetal growth, placental development, and angiogenesis, comprising administering to a female subject or to a maternal subject gestating an unborn baby (e.g., fetus) a composition of the present disclosure. Also disclosed are methods of inhibiting development of a disease or disorder, such as preeclampsia or fetal growth reduction (FGR), in a subject, comprising administering to a female subject or to a maternal subject gestating an unborn baby (e.g., fetus) a composition of the present disclosure.

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

Abstract: Provided herein are methods for selecting a subject with a disease or disorder for treatment, as well as methods of treating the subject, determining the efficacy of the treatment, and adjusting the treatment dosage and frequency.

Abstract: Provided herein are methods and compositions related to promoting or reducing colonization of spore-forming bacteria in a patient's gut, comprising administering a serotonin receptor agonist or a selective serotonin reuptake inhibitor, respectively. In some aspects, provided herein are methods of modulating lipid and steroid metabolism.

Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.